{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:55:22Z","timestamp":1781646922577,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Frankfurt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of this study is to evaluate the safety and clinical outcomes of combined transarterial chemoembolization (TACE) and microwave ablation (MWA) as well as TACE monotherapy in patients with unresectable pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Between 2010 and 2023, 150 patients with unresectable locally advanced pancreatic cancer were included in this retrospective single-center study and treated with either combined TACE and MWA (Group A, n = 67) or TACE alone (Group B, n = 83). In Group A, 23\/67 (34.3%) patients presented with metastatic disease and in Group B 45\/83 (54.2%) patients had metastatic disease. A total of 222 TACE procedures and 71 MWA procedures were performed in Group A, while 250 TACE procedures were performed in Group B. Follow-up was performed using contrast-enhanced cross-sectional imaging and clinical evaluation. Tumor response and overall survival were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean tumor diameter was 3.4 \u00b1 0.9 cm in Group A and 4.9 \u00b1 1.3 cm in Group B. No major complications occurred in either treatment group. Minor hemorrhage following MWA was observed in 4\/71 ablations (5.6%) without further clinical consequence. In Group A, follow-up imaging was available for 47\/67 patients, with local tumor progression observed in 5\/47 patients (10.6%). The 1-year overall survival rate was 69.4%, with a median overall survival time of 14.6 months (95% CI 12.6\u201316.7 months). In Group B, follow-up imaging was available for all 83 patients, with local tumor progression observed in 8\/83 patients (9.6%). The 1-year overall survival rate was 43.6%, with a median overall survival time of 9.0 months (95% CI 3.3\u201314.7 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TACE and MWA were safe locoregional treatments for patients with unresectable pancreatic cancer. Both treatment protocols, including the combination of TACE with MWA and TACE as monotherapy, were effective and showed promising results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06463-3","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:15:00Z","timestamp":1774973700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interventional management of unresectable pancreatic cancer using transarterial chemoembolization and microwave ablation: a single-center evaluation over 12 years"],"prefix":"10.1007","volume":"152","author":[{"given":"Thomas J.","family":"Vogl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra","family":"Cojocaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamzah","family":"Adwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"5","key":"6463_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/cc2955","volume":"8","author":"V Bewick","year":"2004","unstructured":"Bewick V, Cheek L, Ball J (2004) Statistics review 12: survival analysis. Crit Care 8(5):389\u2013394. https:\/\/doi.org\/10.1186\/cc2955","journal-title":"Crit Care"},{"issue":"10","key":"6463_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.jvir.2013.07.005","volume":"24","author":"G Carrafiello","year":"2013","unstructured":"Carrafiello G, Ierardi AM, Fontana F, Petrillo M, Floridi C, Lucchina N et al (2013) Microwave ablation of pancreatic head cancer: safety and efficacy. J Vasc Interv Radiol 24(10):1513\u20131520. https:\/\/doi.org\/10.1016\/j.jvir.2013.07.005","journal-title":"J Vasc Interv Radiol"},{"issue":"19","key":"6463_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"3","key":"6463_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/1533034616649292","volume":"16","author":"M D\u2019Onofrio","year":"2017","unstructured":"D\u2019Onofrio M, Crosara S, De Robertis R, Butturini G, Salvia R, Paiella S et al (2017) Percutaneous radiofrequency ablation of unresectable locally advanced pancreatic cancer: preliminary results. Technol Cancer Res Treat 16(3):285\u2013294. https:\/\/doi.org\/10.1177\/1533034616649292","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"6463_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3892\/ol.2019.10323","volume":"18","author":"SK Das","year":"2019","unstructured":"Das SK, Wang JL, Li B, Zhang C, Yang HF (2019) Clinical effectiveness of combined interventional therapy as a salvage modality for unresectable pancreatic carcinoma. Oncol Lett 18(1):375\u2013385. https:\/\/doi.org\/10.3892\/ol.2019.10323","journal-title":"Oncol Lett"},{"issue":"4","key":"6463_CR5","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado A, Guddati AK (2021) Clinical endpoints in oncology: a primer. Am J Cancer Res 11(4):1121\u20131131","journal-title":"Am J Cancer Res"},{"key":"6463_CR7","doi-asserted-by":"publisher","first-page":"560952","DOI":"10.3389\/fonc.2020.560952","volume":"10","author":"V Granata","year":"2020","unstructured":"Granata V, Grassi R, Fusco R et al (2020) Assessment of ablation therapy in pancreatic cancer: the radiologist\u2019s challenge. Front Oncol 10:560952. https:\/\/doi.org\/10.3389\/fonc.2020.560952","journal-title":"Front Oncol"},{"issue":"2","key":"6463_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.21037\/gs.2017.11.05","volume":"7","author":"AM Ierardi","year":"2018","unstructured":"Ierardi AM, Biondetti P, Coppola A, Fumarola EM, Biasina AM, Alessio Angileri S et al (2018) Percutaneous microwave thermosphere ablation of pancreatic tumours. Gland Surg 7(2):59\u201366. https:\/\/doi.org\/10.21037\/gs.2017.11.05","journal-title":"Gland Surg"},{"issue":"10039","key":"6463_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388(10039):73\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(16)00141-0","journal-title":"Lancet"},{"issue":"282","key":"6463_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457\u2013481. https:\/\/doi.org\/10.2307\/2281868","journal-title":"J Am Stat Assoc"},{"issue":"77","key":"6463_CR11","first-page":"1305","volume":"54","author":"NJ Lygidakis","year":"2007","unstructured":"Lygidakis NJ, Sharma SK, Papastratis P, Zivanovic V, Kefalourous H, Koshariya M et al (2007) Microwave ablation in locally advanced pancreatic carcinoma: a new look. Hepatogastroenterology 54(77):1305\u20131310","journal-title":"Hepatogastroenterology"},{"issue":"3","key":"6463_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","volume":"262","author":"RCGII Martin","year":"2015","unstructured":"Martin RCGII, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C et al (2015) Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg 262(3):486\u2013494. https:\/\/doi.org\/10.1097\/SLA.0000000000001441","journal-title":"Ann Surg"},{"issue":"3","key":"6463_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1148\/radiol.2021203715","volume":"301","author":"RS Puijk","year":"2021","unstructured":"Puijk RS, Ahmed M, Adam A, Arai Y, Arellano R, de Ba\u00e8re T et al (2021) Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN initiative. Radiology 301(3):533\u2013540. https:\/\/doi.org\/10.1148\/radiol.2021203715","journal-title":"Radiology"},{"issue":"3","key":"6463_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/life13030835","volume":"13","author":"E Punzi","year":"2023","unstructured":"Punzi E, Carrubba C, Contegiacomo A, Posa A, Barbieri P, De Leoni D et al (2023) Interventional radiology in the treatment of pancreatic adenocarcinoma: present and future perspectives. Life (Basel) 13(3):835. https:\/\/doi.org\/10.3390\/life13030835.","journal-title":"Life (Basel)"},{"issue":"1","key":"6463_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Gaduputi V (2019) Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 10(1):10\u201327. https:\/\/doi.org\/10.14740\/wjon1166","journal-title":"World J Oncol"},{"issue":"9 Pt 2","key":"6463_CR16","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1097\/01.RVI.0000094584.83406.3e","volume":"14","author":"D Sacks","year":"2003","unstructured":"Sacks D, McClenny TE, Cardella JF, Lewis CA (2003) Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol 14(9 Pt 2):S199\u2013S202. https:\/\/doi.org\/10.1097\/01.rvi.0000094584.83406.3e","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"6463_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"Cancer J Clin"},{"issue":"Suppl 1","key":"6463_CR18","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1148\/rg.25si055501","volume":"25","author":"CJ Simon","year":"2005","unstructured":"Simon CJ, Dupuy DE, Mayo-Smith WW (2005) Microwave ablation: principles and applications. Radiographics 25(Suppl 1):S69\u2013S83. https:\/\/doi.org\/10.1148\/rg.25si055501.","journal-title":"Radiographics"},{"issue":"4","key":"6463_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB et al (2021) Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(4):439\u2013457. https:\/\/doi.org\/10.6004\/jnccn.2021.0017","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"6463_CR20","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3390\/cancers13071608","volume":"13","author":"FEF Timmer","year":"2021","unstructured":"Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ et al (2021a) Locoregional treatment of metastatic pancreatic cancer utilizing resection, ablation and embolization: a systematic review. Cancers (Basel) 13(7):1608. https:\/\/doi.org\/10.3390\/cancers13071608","journal-title":"Cancers (Basel)"},{"issue":"6","key":"6463_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11912-021-01057-3","volume":"23","author":"FEF Timmer","year":"2021","unstructured":"Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ et al (2021b) Locally advanced pancreatic cancer: percutaneous management using ablation, brachytherapy, intra-arterial chemotherapy, and intratumoral immunotherapy. Curr Oncol Rep 23(6):68. https:\/\/doi.org\/10.1007\/s11912-021-01057-3.","journal-title":"Curr Oncol Rep"},{"issue":"1118","key":"6463_CR22","doi-asserted-by":"publisher","first-page":"20200702","DOI":"10.1259\/bjr.20200702","volume":"94","author":"A Uysal","year":"2021","unstructured":"Uysal A, Unal E, Karaosmanoglu AD et al (2021) The role of interventional radiology in the treatment of patients with pancreatic cancer. Br J Radiol 94(1118):20200702. https:\/\/doi.org\/10.1259\/bjr.20200702","journal-title":"Br J Radiol"},{"issue":"11","key":"6463_CR23","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1055\/s-2007-963568","volume":"179","author":"TJ Vogl","year":"2007","unstructured":"Vogl TJ, Zangos S, Heller M, Hammerstingl RM, B\u00f6cher E, Jacob U et al (2007) Transarterielle Chemoperfusion mit Gemcitabine und Mitomycin C bei Pankreaskarzinom: Ergebnisse bei Rezidivtumoren und fortgeschrittenen Tumorstadien [Transarterial chemoperfusion with gemcitabine and mitomycin C in pancreatic carcinoma: results in locally recurrent tumors and advanced tumor stages]. Rofo 179(11):1181\u20131188. https:\/\/doi.org\/10.1055\/s-2007-963568","journal-title":"Rofo"},{"issue":"21","key":"6463_CR24","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.3390\/cancers15215239","volume":"15","author":"TJ Vogl","year":"2023","unstructured":"Vogl TJ, Lilienthal C, Gruber-Rouh T, Afraz Z, Adwan H (2023) Degradable starch microspheres transarterial chemoembolization with or without lipiodol for liver metastases from pancreatic cancer: a prospective randomized trial. Cancers (Basel) 15(21):5239. https:\/\/doi.org\/10.3390\/cancers15215239.","journal-title":"Cancers (Basel)"},{"issue":"40","key":"6463_CR25","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.3748\/wjg.v16.i40.5104","volume":"16","author":"YP Zou","year":"2010","unstructured":"Zou YP, Li WM, Zheng F, Li FC, Huang H, Du JD et al (2010) Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol 16(40):5104\u20135110. https:\/\/doi.org\/10.3748\/wjg.v16.i40.5104","journal-title":"World J Gastroenterol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06463-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06463-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06463-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:16:10Z","timestamp":1781644570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06463-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6463"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06463-3","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"78"}}